Infliximab and the bone in Crohn's disease.
Franchimont
N
N
Reenaers
C
C
Louis
E
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D003094:Collagen / Q000378:metabolism; D024042:Collagen Type I; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D010012:Osteogenesis / Q000187:drug effects*; D010455:Peptides / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D024042:Collagen Type I; D005765:Gastrointestinal Agents; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D000069285:Infliximab